Collins, P. D. and Sattar, N. (2016) Glycaemic effects of non-statin lipid-lowering therapies. Current Cardiology Reports, 18, 133. (doi: 10.1007/s11886-016-0795-9) (PMID:27864787) (PMCID:PMC5116040)
|
Text
129955.pdf - Published Version Available under License Creative Commons Attribution. 267kB |
Abstract
Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for statins, emerging biochemical and genetic links between lipid metabolism and glycemic control raise the prospect of a broader diabetogenic effect of lipid-lowering therapies. For the novel and powerful PCSK9-inhibitor class available evidence does not support a major glycaemic effect with the results of large scale trials awaited although preliminary genetic data does suggest a link. In contrast, there is clear evidence of a diabetogenic effect for the now outdated but well-studied niacin. For ezetimibe and fibrates, evidence is scarce but currently broadly unconcerning. For now, the glycemic effects of lipid-lowering therapies should have a limited influence on clinical decision-making. Further study in this topical area is needed.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Collins, Dr Patrick and Sattar, Professor Naveed |
Authors: | Collins, P. D., and Sattar, N. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
Journal Name: | Current Cardiology Reports |
Publisher: | Springer US |
ISSN: | 1523-3782 |
ISSN (Online): | 1534-3170 |
Published Online: | 19 November 2016 |
Copyright Holders: | Copyright © 2016 The Authors |
First Published: | First published in Current Cardiology Reports 18:133 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record